Long-term effects of treatment of central precocious puberty with gonadotropin-releasing hormone analogs every three months

Abstract

Background

Gonadotropin-releasing hormone (GnRH) analogs represent the treatment of choice in patients with central precocious puberty (CPP). Recently, GnRH analogs that can be administered every 3 months have been developed and appear to be as safe and effective as one-monthly formulations. However, there are limited data regarding its long term safety and efficacy profile. We aimed to evaluate the long-term safety and efficacy treatment of CPP with GnRH analogs every 3 months.

Methods

We prospectively studied all patients who were diagnosed with CPP in our center between January 2015 and December 2019. All patients were treated with intramuscular leuprolide acetate 11.25 mg every 3 months.

Results

Twenty-four patients with CPP were included in the study. Mean follow-up was 3.1 years. Height gain ranged between 4 and 6 cm. Bone mineral density (BMD) was not affected. Body mass index (BMI) increased in all subjects but none was obese at the end of follow-up.

Conclusions

Treatment of patients with CPP with GnRH analogs every 3 months induces substantial increases in height and does not affect BMI or BMD. Therefore, it represents an attractive option for these young patients.

摘要

背景：促性腺激素释放激素（GnRH）类似物是中枢性早熟（CPP）患者的首选治疗方法。近期每3个月应用1次的GnR类似物研发出来, 似乎和每月一次一样安全有效。但是, 关于其长期安全性和有效性的目前资料有限。我们的研究目的是评估每3个月应用1次GnRH类似物治疗CPP的长期安全性和有效性。

方法：我们前瞻性研究了2015年1月至2019年12月在我们中心诊断为CPP的所有患者。患者每3个月肌注醋酸亮丙瑞林11.25mg。

结果：24例CPP患者纳入研究, 平均随访3.1年。身高增加在4到6厘米之间。骨密度（BMD）不受影响。所有受试者的体重指数（BMI）均增加, 但随访结束时无一人为肥胖。

结论：每3个月应用GnRH类似物治疗CPP患者可显著增加身高, 且不影响BMI或BMD。因此, 对于这些年轻患者来说, 这是一个较好的选择。

Keywords:

• Central precocious puberty
• gonadotropin-releasing hormone analogs
• height
• bone mineral density
• obesity

Disclosure statement

The authors report no conflict of interest.